Last reviewed · How we verify
IDOV-SAFETM
At a glance
| Generic name | IDOV-SAFETM |
|---|---|
| Sponsor | Fudan University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE (EARLY_PHASE1)
- Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
- Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors (EARLY_PHASE1)
- Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDOV-SAFETM CI brief — competitive landscape report
- IDOV-SAFETM updates RSS · CI watch RSS
- Fudan University portfolio CI